FDA advisers vote that lecanemab shows benefit as an Alzheimer’s treatment | CNN

An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer’s drug lecanemab shows “clinical benefit” for the treatment of the disease, paving the way for the medication to be considered for full FDA approval. A decision from the FDA is expected by July 6. Lecanemab, a monoclonal antibody sold under the brand name Leqembi, is one of the first dementia drugs that appears to slow the progression of cognitive decline.

, the FDA says. Some people who get appeared to be higher in people who had a gene called APOE4, which can raise the risk of Alzheimer’s disease or other dementias.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eisai-Biogen Alzheimer's Drug Data Confirms Benefits: FDAUS Food and Drug Administration staff on Wednesday said data from a late-stage trial of Eisai and Biogen's Alzheimer's disease drug suggests it offered a meaningful benefit to patients.
Source: Medscape - 🏆 386. / 55 Read more »

FDA panel weighs US approval for Alzheimer's drug from Eisai and BiogenA panel of expert advisers on Friday began their meeting to discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.
Source: Reuters - 🏆 2. / 97 Read more »